Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route.

ABSTRACT:

Background

Ibrutinib is the only Bruton tyrosine kinase inhibitor (BTKi) with once-daily oral capsule, tablet, and oral suspension formulations approved in the United States across indications of chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, and previously treated chronic graft-versus-host disease, and for mantle cell lymphoma in Europe. Patients with difficulty swallowing capsules or tablets may require alternative formulations or administration options to optimize treatment.

Objectives

To evaluate the relative bioavailability of ibrutinib oral suspension relative to capsule or tablet formulations and to examine compatibility for optimal administration methods.

Methods

Relative bioavailability of ibrutinib oral suspension was

SUBMITTER: Paludo J 

PROVIDER: S-EPMC12743846 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature